spacer
home > ebr > winter 2019 > the advent of nanoparticle contrast agents
PUBLICATIONS
European Biopharmaceutical Review

The Advent of Nanoparticle Contrast Agents

In the area of cancer alone, molecular imaging of targeted contrast agents is likely to reduce the need for biopsies through cell phenotyping of tumours, enable monitoring to ensure the treatment has reached the target cells or a specific tumour, and, for patient follow-up, quantify the effect of chemotherapy on specific cell types (1). Additionally, nanoparticle contrast agents can be used in pathology specimens to assess tumour heterogeneity without the need for destructive testing. These new methods are likely to have flow-on effects for improving treatment efficiency and introducing personalised treatment plans.

The Rise of Computed Tomography

Computed tomography (CT) is a well-established clinical imaging methodology used to assess disease or injury. In fact, over 300 million CT scans are performed worldwide each year. CT imaging, which produces 3D X-ray images, was originally developed in the 1970s, and speed and resolution have both significantly advanced over the past couple of decades. However, this has now reached a plateau, and further advances in traditional CT are unlikely to have any dramatic clinical benefit.

Traditionally, typical contrast agents for CT have included iodine, barium, and, occasionally, gadolinium. Of these three, iodine has been the predominant contrast agent of choice for CT imaging over the past 40 years. Iodine provides excellent contrast between blood vessels and surrounding tissues and improves the diagnostic quality of CT images. Despite very few changes in contrast agents since the development of CT, the field of CT contrast agents is set for a shakeup with the advent of two new CT technologies that leverage the energy information contained within the X-ray photons. For the first time, dual energy and spectral CT introduce the ability to quantify and separate multiple materials, taking CT from a qualitative imaging modality for structural analysis to a quantitative diagnostic tool. The next generation of CT, with novel contrast agents, will be able to answer questions well beyond the basics of disease location and degree.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Hannah Prebble is a Clinical Applications Researcher at MARS Bioimaging, a manufacturer of preclinical spectral CT systems. Hannah has a PhD in spectral imaging of atherosclerosis, with a focus on imaging of microcalcification, intraplaque haemorrhage, and gold nanoparticles targeted to macrophages. She also holds an MSc in biochemistry and cell biology, with a focus on inflammation in macrophages. Hannah supports a number of researchers in areas varying from bone health and metal implant imaging, through to tumour imaging and soft tissue analysis.
spacer
Dr Hannah Prebble
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement